다발성 골수종 | 바이오정보모아

CGTBiologicstaleDonghua ZhangPreclinical

Recurrent/refractory multiple myeloma (Recurrent/refractory multiple myeloma, Recurrent/refractory multiple myeloma (r/r MM) patients received infusion of BCMA-GPRC5D CAR-T cells, r/r MM)

Multiple Myeloma · BCMA

#BCMA#CGT#Preclinical#세포유전치료#CAR-T+3

임상시험 1상태 RECRUITING

AntibodyBiologicstaleSeagen Inc.Phase 2

anti-huCD40 mAb (SGN-40, SGN-40 (anti-huCD40 mAb))

Leukemia, Lymphocytic, Chronic · Multiple Myeloma

#MultipleMyeloma#Antibody#Phase2#항체#면역항체+5

임상시험 1상태 ACTIVE

ADCBiologicstaleSeagen Inc.Phase 1

SGN-CD48A (SGN-CD48A)

Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+1

임상시험 1상태 DISCONTINUED

CGTBiologicstaleWuerzburg University HospitalPhase 2

SLAMF7 CAR-T (SLAMF7 CAR-T)

Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#CGT#Phase2#세포유전치료#CAR-T+2

임상시험 1상태 ACTIVE

AntibodystaleOslo University HospitalPhase 3

daratumumab (Darzalex, Standard treatment of relapse with carfilzomib, dexamethasone, daratumumab)

Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#Antibody#Phase3#항체#면역항체+2

임상시험 1상태 RECRUITING

AntibodystaleJanssenPhase 2

Teclistamab Monotherapy (Teclistamab Monotherapy)

Relapse Multiple Myeloma; Refractory Multiple Myeloma · FRα

#FR#Antibody#Phase2#항체#면역항체+4

임상시험 1상태 RECRUITING

AntibodystaleJanssenPhase 2

FDA-approved (Teclistamab, Teclistamab(FDA-approved))

Multiple Myeloma; Cytokine Release Syndrome · FRα

#FR#Antibody#Phase2#항체#면역항체+4

임상시험 1상태 DISCONTINUED

AntibodystaleRochePhase 2

Tocilizumab at emerging CRS (Tocilizumab at emerging CRS)

Myeloma; Lymphoma · Myeloma

#Myeloma#Antibody#Phase2#항체#면역항체+3

임상시험 1상태 RECRUITING

AntibodyBiologicstaleRochePhase 2

Tocilizumab before CAR-T cell infusion (Tocilizumab before CAR-T cell infusion)

Myeloma; Lymphoma · Myeloma

#Myeloma#Antibody#Phase2#항체#면역항체+3

임상시험 1상태 RECRUITING

CGTBiologicstaleCellectis S.A.Phase 1

UCARTCS1A (UCARTCS1A)

Relapsed/Refractory Multiple Myeloma · FRα

#FR#CGT#Phase1#세포유전치료#CAR-T+4

임상시험 1상태 DISCONTINUED

CGTBiologicstaleDavid WaldPhase 1

UF-KURE-BCMA CAR T-cells (UF-KURE-BCMA CAR T-cells)

Multiple Myeloma; Multiple Myeloma in Relapse · BCMA

#BCMA#CGT#Phase1#세포유전치료#CAR-T+4

임상시험 1상태 DISCONTINUED

ADCBiologicstaleGlaxoSmithKlinePhase 2

Unconjugated belantamab antibody (Unconjugated belantamab antibody)

Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1

임상시험 1상태 RECRUITING

ADCBiologicstaleGlaxoSmithKlinePhase 2

belantamab mafodotin (Blenrep, GSK2857916, Unconjugated belantamab antibody and belantamab mafodotin)

Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1

임상시험 1상태 RECRUITING

CGTBiologicstaleBioray LaboratoriesPhase 1

Universal BCMA-CD19 CART (Universal BCMA-CD19 CART)

Autoimmune Disease · CD19

#CD19#CGT#Phase1#세포유전치료#CAR-T+3

임상시험 1상태 RECRUITING

CGTBiologicstalePaula C. & Rodger O. Riney Bloo…Phase 1

WS-CART-CS1 (WS-CART-CS1)

Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#CGT#Phase1#세포유전치료#CAR-T+2

임상시험 1상태 RECRUITING

CGTBiologicstaleChengdu Ucello Biotechnology Co…Phase 1

allogeneic umbilical cord blood-derived CAR-T targeting CD19 and BCMA (allogeneic umbilical cord blood-derived CAR-T targeting CD19 and BCMA)

SLE - Systemic Lupus Erythematosus · CD19

#CD19#CGT#Phase1#세포유전치료#CAR-T+3

임상시험 1상태 RECRUITING

CGTBiologicstaleThe Children's Hospital of Zhej…Phase 1

anti-BCMA/CD70-CAR-T cells (anti-BCMA/CD70-CAR-T cells)

CAR T Cell Therapy; Systemic Lupus Erythematosus · BCMA

#BCMA#CGT#Phase1#세포유전치료#CAR-T+4

임상시험 1상태 RECRUITING

CGTBiologicstaleThe First Affiliated Hospital o…Phase 2

anti-CD19 and anti-BCMA CAR (anti-CD19 and anti-BCMA CAR)

Safety and Efficacy · CD19

#CD19#CGT#Phase2#세포유전치료#CAR-T+3

임상시험 1상태 RECRUITING

CGTBiologicstaleJieyang People's HospitalPhase 1

anti-CD19/BCMA CAR NK cells (anti-CD19/BCMA CAR NK cells)

IgA Nephropathy (IgAN) · CD19

#CD19#CGT#Phase1#세포유전치료#CAR-T+3

임상시험 1상태 DISCONTINUED

CGTBiologicstaleThe Children's Hospital of Zhej…Phase 1

KN5601 (anti-CD19/BCMA CAR NK cells, anti-CD19/BCMA CAR NK cells (KN5601))

Autoimmune Diseases; Systemic Lupus Erthematosus · CD19

#CD19#CGT#Phase1#세포유전치료#CAR-T+4

임상시험 1상태 RECRUITING

11 / 12 페이지

← 이전 다음 →

갱신 기록 없음 · 14일 주기 · 방문 175 / 5,301